BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), […]
–Sustained progress across clinical development programs spanning liver, retinal and metabolic diseases and cancer––Aldafermin continues to advance toward late-stage [...]
Results reflect strong cost management and execution in challenging environmentEnded quarter with $2.8 billion of unrestricted cash, cash equivalents and […]